As backers of other drug developers with CAR T cell therapies in the works scrambled to downplay the hitch met by Juno Therapeutics Inc. and gain distance from it, CEO Hans Bishop outlined what he called "a clear path forward" with JCAR015 in acute lymphoblastic leukemia, held up by the FDA because three patients died in phase II trials.